Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel - PubMed
a day ago
- #dermatology
- #atopic dermatitis
- #nonsteroidal therapies
- Advanced topical nonsteroidal therapies are expanding treatment options for atopic dermatitis (AD) by providing targeted anti-inflammatory control without the limitations of long-term topical corticosteroids.
- An expert panel of seven dermatologists developed consensus statements on the use of advanced topical nonsteroidal therapies in AD through a structured Delphi process.
- The panel unanimously agreed on seven statements regarding therapies like topical ruxolitinib, tapinarof, roflumilast, crisaborole, tacrolimus, pimecrolimus, and delgocitinib.
- These therapies are effective in reducing AD signs and symptoms, including pruritus, and are suitable as first-line agents for many patients.
- Use of these therapies is associated with longer disease control, fewer relapses, and reduced cumulative topical corticosteroid exposure.
- The panel noted improvements in patient-reported outcomes, including quality of life and sleep, and the ability to safely combine these therapies with other treatments.
- Nonsteroidal therapies have favorable safety and tolerability profiles without the need for baseline or ongoing laboratory monitoring.
- Compared to topical corticosteroids, nonsteroidal therapies are preferred for long-term management to avoid steroid-associated adverse effects and support adherence.
- Advanced topical nonsteroidal therapies are considered appropriate first-line options across all disease severities, supporting sustained disease control and improved quality of life.